EP3226843

ARAGON PHARMACEUTICALS, INC.
Application Number
EP15820351A
Filing Date
Dec 3, 2015
Status
Granted And Under Opposition
Apr 23, 2021
Grant Date
May 26, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3226843B1 was granted on May 26, 2021 by Aragon Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVAFeb 25, 2022ADMISSIBLE

The table below shows the patents of Aragon Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3533792Crystalline Forms Of An Androgen Receptor ModulatorMay 5, 20211
EP3226842Anticancer CompositionsNov 25, 20202
EP3305285Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate CancerSep 2, 20203

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.